Over the last couple of years there have been numerous examples of novel CAR-T cell therapies going into initial phase 1 testing in oncology indications beyond B cell ALL/NHL and multiple myeloma from a variety of research groups as well as industry.

Masking may become important in new CAR-T cell products

An interesting trend to watch is the rise in gene edited CARs – via CRISPR or base editing – to either delete or knockdown various genes in an effort to improve the performance of the product in some way.

What if we could go beyond gene editing and employ creative masking strategies instead, especially in a broader array of tumour types?

Two obvious benefits would be lower risk from immunogenicity and also potentially lower cost of goods involved in the manufacturing process.

In this review we explore some new approaches coming out in the CAR-T cell therapy space and assess their strengths and weaknesses…

To continue reading our latest highlights on oncology new product development including commentary and analysis BSB subscribers can log-in or you can click to access the content.

This content is restricted to subscribers

Posted by